Clinical Trial Update: A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial exploring darolutamide as a PSMA expression enhancer in localized prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)

Snippet

Sponsor: D'Or Institute for Research and Education | Conditions: Prostate Cancer | Phase 2 | Status: UNKNOWN